Below is Validea's guru fundamental report for TWIST BIOSCIENCE CORP (TWST). Of the 22 guru strategies we follow, TWST rates highest using our P/B Growth Investor model based on the published ...

Barclays analyst Luke Sergott maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $52.00. The company’s shares closed last Friday at $52.37.

Twist Bioscience Corp (NASDAQ:TWST) reported record revenue of $88.7 million for the first quarter of 2025, marking a 24% year-over-year increase. The company achieved a gross margin of 48.3% ...

Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago. These figures ...

Black style is taking center stage at the 2025 Met Gala, and this year’s theme celebrates its legacy and innovation. As attendees step into the Metropolitan Museum of Art’s Costume Institute ...

Twist Bioscience (TWST) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Good day. Thank you for standing by. Welcome to Twist Bioscience's 2025 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

2-Year U.S. Treasury Note Continuous Contract $102.734 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $106.500 0.039 0.04% 10-Year U.S. Treasury Note Continuous Contract $109.297 0.063 ...